Novel concept to guide systolic heart failure medication by repeated biomarker testing—results from TIME-CHF in context of predictive, preventive, and personalized medicine
暂无分享,去创建一个
Joël M. H. Karel | Ralf Peeters | Nasser Davarzani | Vinzent Rolny | Evgueni Smirnov | Joël Karel | Thomas Suter | M. Pfisterer | R. D. de Boer | T. Suter | N. Davarzani | E. Smirnov | H. Brunner-La Rocca | R. Peeters | P. Rickenbacher | Sandra Sanders-van Wijk | Micha T. Maeder | Peter Rickenbacher | Rudolf A. de Boer | Dirk Block | Christian Zaugg | Matthias E. Pfisterer | Hans-Peter Brunner-La Rocca | C. Zaugg | S. Sanders-van Wijk | V. Rolny | M. Maeder | D. Block | Sandra Sanders-van Wijk
[1] Takuya Kumazawa,et al. Suppressed Production of Soluble Fms-Like Tyrosine Kinase-1 Contributes to Myocardial Remodeling and Heart Failure , 2016, Hypertension.
[2] C. Brensinger,et al. Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure. , 2011, Journal of the American College of Cardiology.
[3] C. Sueta,et al. A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF) , 2014, Current cardiology reviews.
[4] P. Ponikowski,et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long‐Term Registry , 2013, European journal of heart failure.
[5] Joël M. H. Karel,et al. Ranking Accuracy for Logistic-GEE Models , 2016, IDA.
[6] A. Cohen-Solal,et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. , 2007, Journal of the American College of Cardiology.
[7] M. Rousseau,et al. Sflt-1 in heart failure: relation with disease severity and biomarkers , 2016, Scandinavian journal of clinical and laboratory investigation.
[8] P. Ponikowski,et al. A combined clinical and biomarker approach to predict diuretic response in acute heart failure , 2015, Clinical Research in Cardiology.
[9] T. Perneger. What's wrong with Bonferroni adjustments , 1998, BMJ.
[10] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[11] H. Sabbah,et al. Venous Congestion, Endothelial and Neurohormonal Activation in Acute Decompensated Heart Failure: Cause or Effect? , 2015, Current Heart Failure Reports.
[12] R. Feise. Do multiple outcome measures require p-value adjustment? , 2002, BMC medical research methodology.
[13] R. Ekart,et al. Serum cystatin C-based equation compared to serum creatinine-based equations for estimation of glomerular filtration rate in patients with chronic kidney disease. , 2008, Clinical nephrology.
[14] P. Ponikowski,et al. A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT‐CHF , 2016, European journal of heart failure.
[15] A. V. Peterson,et al. On the regression analysis of multivariate failure time data , 1981 .
[16] K J Rothman,et al. No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.
[17] M. Pfisterer,et al. Management of elderly patients with congestive heart failure--design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). , 2006, American heart journal.
[18] Juerg Schwitter,et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.
[19] P. Albert,et al. Models for longitudinal data: a generalized estimating equation approach. , 1988, Biometrics.
[20] K. Ruparel,et al. The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure. , 2011, Journal of the American College of Cardiology.
[21] Marita G Titler,et al. Cost of hospital care for older adults with heart failure: medical, pharmaceutical, and nursing costs. , 2008, Health services research.
[22] Kevin J. Anstrom,et al. Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. , 2014, JACC. Heart failure.
[23] M. Pfisterer,et al. Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy. , 2012, The American journal of cardiology.
[24] I. Aban,et al. Analysis of the 17-segment left ventricle model using generalized estimating equations , 2016, Journal of Nuclear Cardiology.
[25] G. Fonarow,et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). , 2008, Journal of the American College of Cardiology.
[26] George Divine,et al. Are There Race/Ethnicity Differences in Outpatient Congestive Heart Failure Management, Hospital Use, and Mortality Among an Insured Population? , 2004, Medical care.
[27] M. Pfisterer,et al. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction , 2015, European journal of heart failure.
[28] J. Hanley,et al. Statistical analysis of correlated data using generalized estimating equations: an orientation. , 2003, American journal of epidemiology.
[29] M. Pfisterer,et al. Impact of worsening renal function related to medication in heart failure , 2015, European journal of heart failure.
[30] J. P. Araújo,et al. Low prealbumin is strongly associated with adverse outcome in heart failure , 2014, Heart.
[31] Challenges in personalised management of chronic diseases—heart failure as prominent example to advance the care process , 2015, EPMA Journal.
[32] K Y Liang,et al. Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.
[33] Peter Buser,et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. , 2009, JAMA.
[34] J. Butler,et al. Elevated Soluble Fms-Like Tyrosine Kinase-1 and Placental-Like Growth Factor Levels Are Associated With Development and Mortality Risk in Heart Failure , 2016, Circulation. Heart failure.
[35] C. Frampton,et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.
[36] Wouter Duivesteijn,et al. Advances in Intelligent Data Analysis XVII , 2018, Lecture Notes in Computer Science.
[37] B. McFarlin,et al. Generalized equations for estimating DXA percent fat of diverse young women and men: the TIGER study. , 2010, Medicine and science in sports and exercise.
[38] Yoshinobu Morikawa,et al. Usefulness of soluble Fms-like tyrosine kinase-1 as a biomarker of acute severe heart failure in patients with acute myocardial infarction. , 2009, The American journal of cardiology.
[39] N. André,et al. β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma , 2013, British Journal of Cancer.
[40] J. Butler,et al. Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). , 2014, The American journal of cardiology.
[41] G. Fonarow,et al. Differential mortality association of loop diuretic dosage according to blood urea nitrogen and carbohydrate antigen 125 following a hospitalization for acute heart failure , 2012, European journal of heart failure.
[42] A. Palazzuoli,et al. Natriuretic peptides in heart failure: where we are, where we are going , 2011, Internal and emergency medicine.
[43] M. López-Ibáñez,et al. Hypoalbuminemia in acute heart failure patients: causes and its impact on hospital and long-term mortality. , 2014, Journal of cardiac failure.
[44] J. Cleland,et al. The prognostic value of repeated measurement of N‐terminal pro‐B‐type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction , 2009, European journal of heart failure.
[45] Rostyslav V Bubnov,et al. Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016 , 2016, EPMA Journal.
[46] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.
[47] B. French,et al. Biomarker predictors of cardiac hospitalization in chronic heart failure: a recurrent event analysis. , 2014, Journal of cardiac failure.
[48] S. Anker,et al. Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure. , 2016, European heart journal.
[49] Paul J Rathouz,et al. Performance of weighted estimating equations for longitudinal binary data with drop‐outs missing at random , 2002, Statistics in medicine.
[50] R. Califf,et al. The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. , 2011, Journal of cardiac failure.
[51] Volkmar Falk,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.
[52] Alireza Atri,et al. An Overview of Longitudinal Data Analysis Methods for Neurological Research , 2011, Dementia and Geriatric Cognitive Disorders Extra.